Editing Pfizer (section)

==== Corporate developments and acquisitions ====
In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work=[[Reuters]] |date=September 29, 2020}}</ref> In October 2020, the company acquired Arixa Pharmaceuticals.<ref>{{Cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-snaps-up-antibiotics-maker-arixa-and-its-oral-avycaz-follow-up |title=Biotech Pfizer snaps up antibiotics maker Arixa and its oral Avycaz follow-up |first=Amirah |last=Al Idrus |magazine=Fierce Pharma |date=October 22, 2020}}</ref> In November 2020, using a [[Reverse Morris Trust]] structure, Pfizer merged its off-patent branded and [[generic drug]] business, known as Upjohn, with [[Mylan]] to form [[Viatris]], owned 57% by Pfizer shareholders.<ref>{{Cite news |url=https://www.nasdaq.com/articles/pfizer-completes-combination-of-upjohn-and-mylan-viatris-to-begin-trading-on-nov.-17-2020 |title=Pfizer Completes Combination Of Upjohn And Mylan; Viatris To Begin Trading On Nov. 17 |work=[[Nasdaq]] |date=November 16, 2020}}</ref><ref>{{Cite news |url=https://www.post-gazette.com/business/healthcare-business/2020/11/16/Mylan-merger-Upjohn-Viatris-bresch-coury-Pfizer-cost-cuts-generic-drugs/stories/202011160111 |title=Mylan completes merger with Upjohn to form Viatris |first=Patricia |last=Sabatini |work=[[Pittsburgh Post-Gazette]] |date=November 16, 2020}}</ref>

On January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=[[The Wall Street Journal]] |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |magazine=Fierce Pharma |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/2021/04/28/pfizer-acquires-fungus-fighting-san-diego-biotech |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion.<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc|date=August 23, 2021 }}</ref>

In March 2022, the company acquired [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20220310005794/en/Pfizer-Completes-Acquisition-of-Arena-Pharmaceuticals | title=Pfizer Completes Acquisition of Arena Pharmaceuticals | publisher=[[Business Wire]] | date=March 11, 2022}}</ref><ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work=[[Reuters]] |date=December 13, 2021 |access-date=December 13, 2021}}</ref><ref>{{cite web |title=Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal |url=https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813 |work=[[The Wall Street Journal]] |last=Walker |first=Joseph |date=December 13, 2021 |access-date=December 13, 2021}}</ref> In June 2022, the company acquired ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat [[respiratory syncytial virus]] infections.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-rsv-drug-developer-reviral-up-525-mln-2022-04-07/ | title=Pfizer boosts respiratory drug portfolio with ReViral purchase | newspaper=Reuters | date=April 7, 2022 | last1=Satija | first1=Bhanvi }}</ref><ref>{{Cite web |date=2022-06-10 |title=Pfizer acquires biopharma firm ReViral for up to $525m |url=https://www.pharmaceutical-technology.com/news/pfizer-acquires-biopharma-reviral/ |access-date=2022-06-10 |website=Pharmaceutical Technology }}</ref> In October 2022, the company acquired Biohaven Pharma and its [[calcitonin gene-related peptide]] programs for $11.6 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/?s=110 | title=Pfizer Completes Acquisition of Biohaven Pharmaceuticals | date=October 3, 2022 }}</ref><ref>{{cite press release | url=https://www.businesswire.com/news/home/20220510005676/en/ | title=Pfizer to Acquire Biohaven Pharmaceuticals | date=May 10, 2022}}</ref><ref>{{cite web | url=https://www.biospace.com/article/pfizer-drops-a-cool-11-6-billion-on-migraine-leader-biohaven-/?s=79 | title=Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven | date=May 10, 2022 }}</ref> It also acquired Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20221004006158/en/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics%C2%A0 | title=Pfizer Completes Acquisition of Global Blood Therapeutics | publisher=[[Business Wire]] | date=October 5, 2022}}</ref><ref>{{Cite news |last=Rockoff |first=Jonathan D. |date=2022-08-08 |title=Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/pfizer-reaches-5-4-billion-deal-for-global-blood-therapeutics-11659954601 |access-date=2022-08-08 |issn=0099-9660}}</ref><ref>{{Cite news |date=2022-08-08 |title=Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-global-blood-therapeutics-54-bln-deal-2022-08-08/ |access-date=2022-08-08}}</ref>

In April 2023, Pfizer moved its world headquarters from [[42nd Street (Manhattan)|42nd Street]] in [[Midtown Manhattan]] to the Spiral at [[Hudson Yards (development)|Hudson Yards]].<ref>{{cite news |url=https://www.crainsnewyork.com/health-care/pfizer-opens-global-headquarters-hudson-yards-empty-offices-reach-pandemic-levels |last1=D'Ambrosio |first1=Amanda |title=Pfizer opens global headquarters in Hudson Yards as empty offices reach pandemic levels |work=[[Crain Communications]] |date=April 3, 2023}}</ref><ref>{{cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-moves-west-side-settling-down-swanky-new-digs-hudson-yards-spiral-skyscraper |last1=Liu |first1=Angus |last2=Kansteiner |first2=Fraiser |title=Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraper |magazine=Fierce Pharma |date=April 4, 2023}}</ref>

In December 2023, the company acquired [[Seagen]], a pioneer of [[antibody–drug conjugate]]s for the treatment of cancer, for $43{{nbsp}}billion.<ref>{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher=[[Reuters]]}}</ref><ref>{{Cite press release | url=https://www.businesswire.com/news/home/20231213759493/en/Pfizer-Completes-Acquisition-of-Seagen | title=Pfizer Completes Acquisition of Seagen | publisher=[[Business Wire]] | date=December 14, 2023}}</ref>

On Sept 30, 2024, Pfizer announced its intentions to sell 540 million Haleon shares whose worth is about  £2.1 billion ($2.8 billion)  according to Bloomberg calculations.<ref>{{Cite web |date=October 1, 2024 |title=Pfizer to further reduce stake in Haleon, offers to sell 540 million share |url=https://www.business-standard.com/world-news/pfizer-to-further-reduce-stake-in-haleon-offers-to-sell-540-million-share-124100101515_1.html}}</ref>

In the third quarter of 2024, Pfizer reported $17.7 billion in revenue, a 32% year-over-year increase, driven by [[Nirmatrelvir/ritonavir|Paxlovid]] ($2.7 billion) and [[Pfizer–BioNTech COVID-19 vaccine|Comirnaty]] ($1.4 billion). Excluding COVID-19 products, core revenue grew 14% to $13.6 billion, led by [[Tafamidis|Vyndaqel]] sales (up 63%) and $854 million from legacy Seagen products. The company raised its 2024 revenue guidance to $61.0–$64.0 billion and adjusted diluted earnings per share to $2.75–$2.95. Pfizer remains on track for $5.5 billion in cost savings, with $4 billion expected by 2024 and $1.5 billion by 2027. Reported diluted earnings per share was $0.78, and adjusted diluted earnings per share was $1.06. The company ranks 69th on the [[Fortune 500|''Fortune'' 500]] of the same year.<ref>{{Cite web |date=2024-10-29 |title=Pfizer Delivers Strong Third-Quarter 2024 Financial Results and Raises 2024 Guidance |url=https://insights.pfizer.com/q324earnings/ |access-date=2025-04-02 |website=Pfizer Investor Insights |language=en-US}}</ref>